News Article
Jun 26, 2017
Microbiotica Shortlisted for Biotech and Money’s ‘Life Science Spin-out of the Year’

Cambridge, UK, 26 June 2017

Microbiotica, a leading player in microbiome-based therapeutics, is delighted to announce that it has been shortlisted for the ‘Life Science Spin-out of the Year’ category of the Biotech and Money 2017 Awards.

Microbiotica was selected as a shortlisted finalist for its success as the newest spin-out company from the UK’s world-reknowned Wellcome Trust Sanger Institute, Cambridge, with £8m funding from Cambridge Innovation Capital and IP Group. The judges recognised the Company’s leadership position in understanding how the microbiome can be used to not only develop new therapeutics for a range of diseases but also how to stratify patients according to their microbial profile, identify links with disease and exploit its full potential for human healthcare.

Voting is now open. The winners in each category are determined 50% by this online voting and 50% by a live vote on the night of the Awards dinner, which is held in London on 14 September.